ATE280152T1 - Acetylenische sulfonamid-thiol-tace-inhibitoren - Google Patents
Acetylenische sulfonamid-thiol-tace-inhibitorenInfo
- Publication number
- ATE280152T1 ATE280152T1 AT00905787T AT00905787T ATE280152T1 AT E280152 T1 ATE280152 T1 AT E280152T1 AT 00905787 T AT00905787 T AT 00905787T AT 00905787 T AT00905787 T AT 00905787T AT E280152 T1 ATE280152 T1 AT E280152T1
- Authority
- AT
- Austria
- Prior art keywords
- acetyleneic
- sulfonamide
- thiol
- tace inhibitors
- disease
- Prior art date
Links
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 title 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- -1 rheumatoid arthritis Chemical compound 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23839399A | 1999-01-27 | 1999-01-27 | |
| PCT/US2000/002143 WO2000044716A1 (en) | 1999-01-27 | 2000-01-27 | Acetylenic sulfonamide thiol tace inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE280152T1 true ATE280152T1 (de) | 2004-11-15 |
Family
ID=22897697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00905787T ATE280152T1 (de) | 1999-01-27 | 2000-01-27 | Acetylenische sulfonamid-thiol-tace-inhibitoren |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1149074B1 (de) |
| JP (1) | JP2002535386A (de) |
| KR (1) | KR20010101691A (de) |
| CN (1) | CN1224612C (de) |
| AT (1) | ATE280152T1 (de) |
| AU (1) | AU766192B2 (de) |
| BR (1) | BR0007727A (de) |
| CA (1) | CA2356480A1 (de) |
| CZ (1) | CZ20012545A3 (de) |
| DE (1) | DE60015079T2 (de) |
| DK (1) | DK1149074T3 (de) |
| EA (1) | EA200100811A1 (de) |
| ES (1) | ES2230064T3 (de) |
| HK (1) | HK1038915A1 (de) |
| HU (1) | HUP0105282A3 (de) |
| IL (1) | IL144347A0 (de) |
| NO (1) | NO20013638D0 (de) |
| NZ (1) | NZ512306A (de) |
| PL (1) | PL350420A1 (de) |
| WO (1) | WO2000044716A1 (de) |
| ZA (1) | ZA200105069B (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003033477A1 (en) * | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| SI1465861T1 (sl) | 2001-12-20 | 2009-12-31 | Bristol Myers Squibb Co | Alfa-(n-sulfonamido)acetamidni derivati kot beta-amiloid inhibitorji |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
| US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| US8093276B2 (en) | 2007-10-31 | 2012-01-10 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| CN113194954A (zh) | 2018-10-04 | 2021-07-30 | 国家医疗保健研究所 | 用于治疗角皮病的egfr抑制剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1230884A (zh) * | 1996-07-22 | 1999-10-06 | 孟山都公司 | 硫羟砜金属蛋白酶抑制剂 |
| CZ16899A3 (cs) * | 1996-07-22 | 1999-08-11 | Monsanto Company | Thiolsulfonamidové inhibitory metaloproteázy |
-
2000
- 2000-01-27 HU HU0105282A patent/HUP0105282A3/hu unknown
- 2000-01-27 CA CA002356480A patent/CA2356480A1/en not_active Abandoned
- 2000-01-27 EP EP00905787A patent/EP1149074B1/de not_active Expired - Lifetime
- 2000-01-27 IL IL14434700A patent/IL144347A0/xx unknown
- 2000-01-27 DE DE60015079T patent/DE60015079T2/de not_active Expired - Fee Related
- 2000-01-27 ES ES00905787T patent/ES2230064T3/es not_active Expired - Lifetime
- 2000-01-27 JP JP2000595972A patent/JP2002535386A/ja active Pending
- 2000-01-27 CZ CZ20012545A patent/CZ20012545A3/cs unknown
- 2000-01-27 CN CNB008030286A patent/CN1224612C/zh not_active Expired - Fee Related
- 2000-01-27 EA EA200100811A patent/EA200100811A1/ru unknown
- 2000-01-27 AT AT00905787T patent/ATE280152T1/de not_active IP Right Cessation
- 2000-01-27 KR KR1020017009365A patent/KR20010101691A/ko not_active Application Discontinuation
- 2000-01-27 AU AU27417/00A patent/AU766192B2/en not_active Ceased
- 2000-01-27 BR BR0007727-5A patent/BR0007727A/pt not_active IP Right Cessation
- 2000-01-27 NZ NZ512306A patent/NZ512306A/en unknown
- 2000-01-27 DK DK00905787T patent/DK1149074T3/da active
- 2000-01-27 WO PCT/US2000/002143 patent/WO2000044716A1/en not_active Application Discontinuation
- 2000-01-27 PL PL00350420A patent/PL350420A1/xx not_active Application Discontinuation
-
2001
- 2001-06-20 ZA ZA200105069A patent/ZA200105069B/en unknown
- 2001-07-24 NO NO20013638A patent/NO20013638D0/no not_active Application Discontinuation
-
2002
- 2002-01-18 HK HK02100417.3A patent/HK1038915A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2356480A1 (en) | 2000-08-03 |
| KR20010101691A (ko) | 2001-11-14 |
| ES2230064T3 (es) | 2005-05-01 |
| CN1337947A (zh) | 2002-02-27 |
| BR0007727A (pt) | 2001-10-30 |
| CZ20012545A3 (cs) | 2002-04-17 |
| CN1224612C (zh) | 2005-10-26 |
| JP2002535386A (ja) | 2002-10-22 |
| HUP0105282A2 (hu) | 2002-05-29 |
| HK1038915A1 (zh) | 2002-04-04 |
| DE60015079T2 (de) | 2005-03-03 |
| DK1149074T3 (da) | 2005-01-10 |
| NO20013638L (no) | 2001-07-24 |
| PL350420A1 (en) | 2002-12-16 |
| EP1149074A1 (de) | 2001-10-31 |
| DE60015079D1 (de) | 2004-11-25 |
| AU2741700A (en) | 2000-08-18 |
| ZA200105069B (en) | 2002-09-20 |
| WO2000044716A1 (en) | 2000-08-03 |
| IL144347A0 (en) | 2002-05-23 |
| HUP0105282A3 (en) | 2005-04-28 |
| NO20013638D0 (no) | 2001-07-24 |
| AU766192B2 (en) | 2003-10-09 |
| EA200100811A1 (ru) | 2002-12-26 |
| EP1149074B1 (de) | 2004-10-20 |
| NZ512306A (en) | 2003-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200102132T2 (tr) | Asetilenik alfa-amino asit temelli sülfonamid hidroksamik asit tace inhibitörleri. | |
| ATE280152T1 (de) | Acetylenische sulfonamid-thiol-tace-inhibitoren | |
| HK1067120A1 (en) | Glutaminyl based dpiv inhibitors | |
| NZ512446A (en) | Alkynyl containing hydroxamic acid compounds as TACE inhibitors | |
| EA200200890A1 (ru) | Применение ингибиторов il-18 | |
| NZ511885A (en) | 2,3,4,5-tetrahydro-1H-[1,4]benzodiazephine-3-hydroxamic acid as matrix metalloproteinase inhibitors and as inhibitors of TNF-alpha converting enzyme (TACE) | |
| ES2193241T3 (es) | Nuevas n-2-oxo2.3.4.5-tetrajodrp-1h-1,5-benzodiazepin-3-il)-3-amidas. | |
| YU67900A (sh) | Sukcinamidni inhibitori interleukin-1beta konvertujućeg enzima | |
| DE60012302D1 (en) | Acetylenische arylsulfonamid- und phosphinsäureamid-hydroxamsäure-derivate als tace inhibitoren | |
| EE200000594A (et) | Keemiline lisand pinnase insenertehniliste omaduste parendamiseks | |
| DK1109818T3 (da) | Phosphoepoxider, fremgangsmåder til deres fremstilling og deres anvendelser | |
| BG104292A (en) | Methods and compositions for the treatment of rheumatoid arthritis | |
| SI1620423T1 (sl) | Postopek za pripravo (4-hidroksi-6-okso-tetrahidro-piran-2-il)-aceetonitrila in njihovih derivatov | |
| MXPA04004010A (es) | Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz. | |
| EA200100808A1 (ru) | ГИДРОКСАМОВЫЕ КИСЛОТЫ НА ОСНОВЕ АЦЕТИЛЕНОВОГО b-СУЛЬФОНАМИДО И АМИДА ФОСФИНОВОЙ КИСЛОТЫ, КАК ИНГИБИТОРЫ TACE | |
| YU18399A (sh) | Postupak alkilacije zaštićenih sulfonamida | |
| EP1279674A3 (de) | Acetylenische ortho-Sulfonamido- und Phosphinsäure-amido-bizyklische Heteroarylhydroxamsäure als TACE-Inhibitoren | |
| EA200100805A1 (ru) | Ингибиторы tace на основе гетероарилацетиленсульфонамида и фосфинамида гидроксамовой кислоты | |
| BR0311590A (pt) | Agonistas de brs-3 não-peptìdicos | |
| NO20014845L (no) | Anvendelse av arylalkanoylpyridaziner | |
| WO2002010160A3 (de) | Substituierte heterocyclylalkylamino-1,3,5-triazine | |
| ATE303390T1 (de) | Sulfat von cephemverbindung | |
| DK0691986T3 (da) | Hidtil ukendte fremgangsmåder og mellemproduktforbindelser til fremstillingen af blodpladeglycoprotein IIb/IIIa-inhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |